Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.14 (-10.94%)

    Market Cap: $155.74M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fate Therapeutics Inc (FATE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Fate Therapeutics reported revenue of $6.65M for the fiscal year ended Dec 31, 2025, down 51.2% from the year before. That year, net income was -$136.31M with a net margin of -2051.1%, operating cash flow was -$106.08M and free cash flow was -$112.04M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$30.69M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $4.40M, a compound annual rate of 4.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$6.65M-51.2%100.0%-2222.4%-2051.1%
    Dec 2024$13.63M-78.5%100.0%-1542.6%-1366.5%
    Dec 2023$63.53M-34.0%100.0%-299.9%-253.3%
    Dec 2022$96.30M+72.4%100.0%-320.2%-292.5%
    Dec 2021$55.85M+77.7%100.0%-388.6%-379.9%
    Dec 2020$31.43M+194.3%100.0%-407.5%-551.6%
    Dec 2019$10.68M+125.3%100.0%-943.1%-919.0%
    Dec 2018$4.74M+15.4%100.0%-1415.4%-1405.0%
    Dec 2017$4.11M-6.7%100.0%-1025.9%-1046.1%
    Dec 2016$4.40MN/A100.0%-726.1%-760.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$6.65M$13.63M$63.53M$96.30M$55.85M$31.43M$10.68M$4.74M$4.11M$4.40M
    Gross profit$6.65M$13.63M$63.53M$96.30M$55.85M$31.43M$10.68M$4.74M$4.11M$4.40M
    Research and development$107.83M$135.00M$172.60M$320.45M$215.52M$125.62M$87.77M$56.02M$34.36M$26.45M
    Operating income-$147.70M-$210.28M-$190.51M-$308.39M-$216.99M-$128.09M-$100.73M-$67.09M-$42.13M-$31.96M
    Net income-$136.31M-$186.26M-$160.93M-$281.72M-$212.15M-$173.39M-$98.15M-$66.60M-$42.95M-$33.46M
    EBITDA-$138.07M-$193.67M-$164.03M-$271.38M-$198.55MN/A-$98.28M-$65.61M-$41.10M-$30.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$2.08M$1.30M$1.37M$1.74M$1.91M$1.63M$1.86M$3.07M$6.77M$1.93M$1.68M
    Gross profit$0$2.08M$1.30M$1.37M$1.74M$1.91M$1.63M$1.86M$3.07M$6.77M$1.93M$1.68M
    Operating income-$32.25M-$31.13M-$33.00M-$34.72M-$34.73M-$36.97M-$41.28M-$61.75M-$52.38M-$45.08M-$51.07M-$48.08M
    Net income-$30.69M-$30.16M-$31.21M-$32.37M-$32.25M-$34.07M-$37.62M-$52.15M-$47.68M-$38.43M-$48.00M-$44.12M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $4.56M by $42.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$318.94M$440.69M$506.22M$705.56M$921.46M$622.46M$302.27M$213.03M$105.29M$95.05M
    Current assets$208.70M$291.91M$331.54M$502.07M$633.41M$494.32M$227.09M$205.20M$102.60M$93.32M
    Cash and equivalents$46.63M$36.06M$41.87M$61.33M$133.58M$167.35M$99.81M$190.51M$88.95M$88.61M
    Total liabilities$111.75M$121.97M$137.80M$221.62M$242.62M$238.01M$57.52M$52.56M$28.10M$21.89M
    Short-term debt$4.56M$7.42M$6.18M$5.63M$5.58M$3.35M$1.69M$2.44M$0$8.19M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$12.45M$14.81M$2.50M
    Shareholder equity$207.18M$318.73M$368.42M$483.94M$678.84M$384.44M$244.76M$160.47M$77.19M$73.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$238.28M$260.10M$284.92M$318.94M$343.67M$371.63M$398.67M$440.69M$494.97M$528.82M$569.89M$506.22M
    Total liabilities$105.24M$106.67M$105.21M$111.75M$109.61M$110.27M$110.26M$121.97M$132.64M$131.84M$143.78M$137.80M
    Cash and equivalents$43.94M$32.43M$39.57M$46.63M$40.62M$41.25M$44.92M$36.06M$37.91M$36.92M$121.32M$41.87M
    Shareholder equity$133.03M$153.44M$179.71M$207.18M$234.07M$261.36M$288.41M$318.73M$362.33M$396.98M$426.12M$368.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$106.08M-$122.87M-$132.26M-$248.21M-$162.87M-$39.23M-$83.17M-$38.65M-$36.82M-$29.82M
    Capital expenditures$5.95M$730.00K$6.15M$35.57M$50.70M$4.93M$7.39M$2.30M$1.73M$457.00K
    Free cash flow-$112.04M-$123.60M-$138.42M-$283.77M-$213.57M-$44.16M-$90.57M-$40.95M-$38.54M-$30.28M
    Dividends paidN/AN/AN/AN/AN/AN/A$2.52MN/A$15.21M$186.00K
    Investing cash flow$111.17M$12.22M$112.67M$166.75M-$324.02M-$161.08M-$157.45M-$463.00K-$10.20M-$4.11M
    Financing cash flow$5.49M$99.89M$85.00K$9.21M$453.13M$282.84M$149.93M$140.78M$47.36M$57.74M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$27.89M-$23.43M-$30.82M-$23.31M-$24.37M-$24.59M-$33.81M-$27.80M-$29.42M-$32.31M-$33.35M-$36.64M
    Capital expendituresN/A$80.00K$239.00K$1.19M$2.20M$1.36M$1.20M$98.00K$495.00K$51.00K$86.00K$181.00K
    Free cash flowN/A-$23.51M-$31.06M-$24.51M-$26.58M-$25.95M-$35.01M-$27.90M-$29.91M-$32.36M-$33.44M-$36.82M
    Last 12 quarters

    Frequently Asked Questions About FATE

    What is Fate Therapeutics' annual revenue?

    Fate Therapeutics reported revenue of $6.65M for the fiscal year ended Dec 31, 2025.

    How fast is Fate Therapeutics' revenue growing?

    Revenue was down 51.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -59.0%.

    Is Fate Therapeutics profitable?

    No. Fate Therapeutics reported net income of -$136.31M for the fiscal year ended Dec 31, 2025, with a net margin of -2051.1%.

    How much free cash flow does FATE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$106.08M minus capital expenditures of $5.95M produced free cash flow of -$112.04M.

    How much debt does Fate Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $4.56M and cash and equivalents of $46.63M.